HOME / Blog

GeneGoCell Insights

Stay informed, stay productive with all the latest from GeneGoCell.

All Genome Editing Safety Genome Editing Verification Off-target Analysis Chromosomal Translocation Analysis Cell and Gene Therapy FDA Gene Therapy Guidance G-Screen℠ G-LMP℠ G-Int℠ GEV℠ Genome Editing Integration Analysis Integration Site Analysis Transgene Integrity Genome Editing Ethics Independent Verification G-Trans℠ Genome Editing Translocation Analysis On-target Verification G-Amp℠ G-GUIDE℠ Off-Target analysis CRISPR off-target identification Cell And Gene Therapy G-Amp-HT℠ High-Throughput NGS Genotyping Clone Genotyping NGS Testing Cell Line Engineering in vivo CAR CAR cell therapy CAR cell therapy beyond cancer CGT testing Genomics Biotech Entrepreneurship
What Must Be Measured, and What Can Be Shared: NGS, prior knowledge, and genome-editing safety in three 2026 FDA publications

What Must Be Measured, and What Can Be Shared: NGS, prior knowledge, and genome-editing safety in three 2026 FDA publications

By Dr. Aaron Zhang-Chen, CQA, PhD on August 31, 2026

What do three 2026 FDA guidance/recommendation mean for genome editing? Learn what NGS safety data should be measured, what prior knowledge can be reused, and when.
Genome Editing SafetyGenome Editing VerificationOff-target AnalysisChromosomal Translocation AnalysisCell and Gene TherapyFDA Gene Therapy Guidance
High-Resolution, Customizable, and Cost-Effective: Genome Editing Verification (GEV℠) G-Amp℠ Workflow Delivers It All

High-Resolution, Customizable, and Cost-Effective: Genome Editing Verification (GEV℠) G-Amp℠ Workflow Delivers It All

By Dr. Aaron Zhang-Chen, CQA, PhD on July 21, 2026

Discover how GeneGoCell's Genome Editing Verification (GEV℠) G-Amp℠ platform improves multiplex targeted amplicon sequencing with dual-amplicon, UMI technology for accurate, sensitive, and cost-effective NGS analysis of gene editing outcomes.
Genome Editing VerificationOn-target VerificationOff-target AnalysisG-Amp℠GEV℠